TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the second quarter ending June 30, 2012. at Cohen-Dayag, Ph.D., President and CEO of Compugen, stated, “Among our notable achievements during this past quarter was the initiation of operations at Compugen Inc., our South San Francisco subsidiary established for the development of monoclonal antibody therapeutic candidates (mAbs) against Compugen’s novel pre-clinically validated targets.”
